Evidence map›Paper›PMID 30535743›Full record

ArticleEndocrine2019

Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.

Joseph Zhou, Anil Poudel, Prashanth Chandramani-Shivalingappa, Biao Xu, Ryan Welchko, Lixin Li

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Joseph ZhouCollege of Medicine, Central Michigan University, Mount Pleasant, MI, 48859, USA.
Anil PoudelDepartment of Physician Assistant, College of Health Professions, Central Michigan University MI, Mount Pleasant, MI, 48859, USA.
Prashanth Chandramani-ShivalingappaDepartment of Physician Assistant, College of Health Professions, Central Michigan University MI, Mount Pleasant, MI, 48859, USA.
Biao XuDepartment of Cardiology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.
Ryan WelchkoDepartment of Physician Assistant, College of Health Professions, Central Michigan University MI, Mount Pleasant, MI, 48859, USA.
Lixin LiDepartment of Physician Assistant, College of Health Professions, Central Michigan University MI, Mount Pleasant, MI, 48859, USA. li6l@cmich.edu.ORCID 0000-0003-3016-4228
Central Michigan University · USNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlucagon like peptide-1 (GLP-1) is produced to induce postprandial insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, has a protective effect on weight gain in obese subjects. Brown adipose tissue plays a major role in the control of energy balance and is known to be involved in the weight loss regulated by liraglutide. The putative anti-obesity properties of liraglutide and the cell signaling pathways involved were examined.

methodsFour groups of C57/BL6 mice fed with chow or HFHS diet were injected with either liraglutide or vehicle for four weeks. Western blotting was used to analyze protein expression.

resultsLiraglutide significantly attenuated the weight gain in mice fed with HFHS diet and was associated with significant reductions of epididymal fat and inguinal fat mass. Furthermore, liraglutide significantly upregulated the expression of brown adipose-specific markers in perigonadal fat in association with upregulation of AMPK-SIRT-1-PGC1-α cell signaling. However, elevation of brown fat markers in skeletal muscle was only observed in HFHS diet fed mice after liraglutide treatment, and AMPK-SIRT-1 cell signaling is not involved in this process.

conclusionsthe anti-obesity effect of liraglutide occurs through adaptive thermogenesis and may act through different cell signaling pathways in fat and skeletal muscle tissue. Liraglutide induces beige fat development partially through the AMPK-SIRT-1-PGC1-α cell signaling pathway. Therefore, liraglutide is a potential medication for obesity prevention and in targeting pre-diabetics.

Indexed as

Adenylate KinaseAdipose Tissue, BeigeAdiposityAnimalsDiet, High-FatHypoglycemic AgentsLipogenesisLiraglutideMaleMiceMitochondriaObesityPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaSignal TransductionSirtuin 1Adenylate KinaseHypoglycemic AgentsLiraglutidePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPpargc1a protein, mouseSirtuin 1Beige fatDiet induced obesityInsulin resistanceLiraglutide

Identifiers

PMID30535743
OpenAlexW2903705615

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.